Jo Wiederhorn
President and Chief Executive Officer

Jo Wiederhorn earned her Bachelor’s degree at the University of Minnesota and her Masters of Social Work at Rutgers University. She began her career as a public health analyst at the New Jersey Department of Health, where she ultimately became the Director of Addiction Treatment and Rehabilitation Services. In 1996, she moved to New York City to work at the New York City Health and Hospitals Corporation (HHC) where she held the positions of Chief of Staff to the President and Associate Executive Director of Metroplus-HHC’s Medicaid Managed Care Plan. Ms. Wiederhorn was then recruited to NYU School of Medicine, where she served as Chief of Staff to the Dean. While working there, she started the school’s Institute for Urban and Global Health, which studied the linkage between urban health problems and global health conditions. In 2002, Ms. Wiederhorn became the President and CEO of the Associated Medical Schools of New York (AMSNY) and the New York State Academic Dental Centers (NYSADC). In this role, she advocates in Albany and Washington DC for NYS’ sixteen medical schools and five dental schools on issues related to the schools’ three core missions: education, research and patient care.

Jonathan Teyan, MPA
Chief Operating Officer

Jonathan Teyan joined AMSNY in 2011 and currently serves as Chief Operating Officer. In this role, he is responsible for a portfolio of initiatives in biomedical research, medical education, global health and government affairs. Jonathan began a peripatetic career in science studying conservation biology at Cornell University, then at the National Audubon Society, where he directed that organization’s largest environmental education center. After a five-year stint at Audubon, he completed an MPA in Management at Columbia University’s School of International and Public Affairs, where began a longstanding interest in public health policy. Jonathan then joined AMDec Foundation, where he worked with genomic scientists, diabetes researchers and spearheaded the development of a $20M shared-use transgenic mouse breeding facility. Jonathan has also worked as a science writer and consulted for biomedical startups.